Roche spent more than $10 billion to buy Boehringer Mannheim. Now it has to justify its investment. Roche believes that the outlook for diagnostics is bright and it sees growth in all of its four diagnostic business units, particularly patient care and molecular systems.
by Wendy Diller
Jean-Luc Bélingard, then head of Roche Diagnostics , a division of Roche , was in a bind in...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
